---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019872"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:35:59.257127+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma CMO Arturo Molina resigns; effective Nov 4, 2022

## Summary
- Dr. Arturo Molina notified Sutro on Oct 18, 2022 of his resignation as Chief Medical Officer.
- Resignation effective November 4, 2022; no successor announced.
- Company states resignation not due to any disagreement with management or board.

## SEC filing metadata
- accession: 0000950170-22-019872
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017022019872/0000950170-22-019872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017022019872/stro-20221018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019872
- JSON: https://secwatch.observer/filing/0000950170-22-019872.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019872.txt

## Key facts
- Executive change
  Arturo Molina resigned as Chief Medical Officer at SUTRO BIOPHARMA, INC..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On October 18, 2022, Dr. Arturo Molina notified Sutro Biopharma, Inc. (the “ Company ”) that he will resign from his role as Chief Medical Officer of the Company, effective November 4, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017022019872/0000950170-22-019872-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.